Jay Keasling
From Wikipedia, the free encyclopedia
Jay D. Keasling is a Professor of Chemical Engineering and Bioengineering at the University of California, Berkeley. He is also the Director of the Physical Biosciences Division of the Lawrence Berkeley National Laboratory, and is the Founding Director of the Synthetic Biology Department at UC Berkeley. He is considered one of the foremost authorities in Synthetic Biology, especially in the field of metabolic engineering.
Keasling's current research involves the metabolic engineering of the Escherichia coli bacterium, to produce the anti-malarial drug Artemisinin. Although it is an effective, proven treatment for malaria, current methods of producing Artemisinin (found naturally in the plant Artemisia annua) are considered too expensive to cost-effectively eliminate malaria from developing countries. By producing the drug from a microbe, rather than harvesting it from a plantation, the Keasling Lab intends to lower the cost of artemisin production from $2.40 per dose to $0.25 per dose.
In 2004, the Bill and Melinda Gates Foundation awarded a shared $42.5 million grant to the Keasling Lab, Amyris Biotechnologies, and the Institute for OneWorld Health to develop and distribute the low-cost malaria treatment.
Jay Keasling received his Bachelor's Degree at the University of Nebraska-Lincoln. He received his Ph.D from the University of Michigan in 1991.
